BusinessGeneral NewsHealthcareIndustry

Thalassemia Market 2020 Scope, Demand and Global Outlook-Fresenius Kabi AG; Pfizer Inc.; bluebird bio, Inc.; Acceleron Pharma, Inc.; Incyte Corporation; Kiadis Pharma

Global Thalassemia Market is expected to rise from its initial estimated value of USD 1.99 billion to a projected value of USD 4.36 billion by 2026, registering a CAGR of 10.29% in the forecast period of 2019-2026. This rise in market value can be attributed to the increasing concern and awareness regarding the disease globally.

The international Thalassemia market report provides in-depth evaluation on a global and regional level. The report study offers historic facts and forecasted data. The document consists of a complete evaluation of factors impacting the growth of the market. It also evaluates the driving forces of the global market and changing dynamics that have been considered as a boom-boosting factor. This Thalassemia business research report includes current and future developments, possibilities, and threats of the market. Here, the market is studied based on segments along with type, application, and end-user. The report consists of an exhaustive qualitative and quantitative analysis of these segments.

Get Sample Copy Of This Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-thalassemia-market

Few of the major competitors currently working in the thalassemia market are ApoPharma Inc.; Novartis AG; Teva Pharmaceutical Industries Ltd.; Fresenius Kabi AG; Pfizer Inc.; bluebird bio, Inc.; Acceleron Pharma, Inc.; Incyte Corporation; Kiadis Pharma; Gamida Cell; CELGENE CORPORATION; GlaxoSmithKline plc; Ionis Pharmaceuticals, Inc.; Vifor Pharma; La Jolla Pharmaceutical Company; Lonza and Sangamo Therapeutics.

Key Developments in the Market:

In April 2019, CELGENE CORPORATION and Acceleron Pharma, Inc. announced that CELGENE had submitted a Biologics License Application (BLA) for “luspatercept” with the U.S. F.D.A. (United States Food & Drug Administration). This will help in faster commercialization and development of drugs for patients suffering from blood diseases.
In January 2019, Vifor Pharma announced positive results from their phase-I trial of “VIT-2763” an oral ferroportin inhibitor. The drug being developed for transportation of iron from one cell to another has shown signs in reduction of serum iron in a dose-dependent state.
COMPETITIVE ANALYSIS:
Global thalassemia market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of thalassemia market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Inquiry For Customize Report With Discount at : https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-thalassemia-market

Segmentation: Global Thalassemia Market

By Thalassemia Type

Alpha Thalassemia
Beta Thalassemia

By Therapeutic Class

Iron Chelating Drugs
Exjade/Jadenu (deferasirox)

By Pipeline

Gene Therapy
LentiGlobin

By End-User

Hospitals
Clinics
Research Institutes
Laboratories

By Geography

North America
South America
Europe
Asia-Pacific
Middle East & Africa

Market Drivers

Increasing prevalence of the disease globally without any viable treatment options available for curing the disease; this factor is expected to drive the market growth
Growth in development of pipeline drugs and development of new therapies because of R&D activities and investments by the various authorities; this factor is expected to drive the market growth

Market Restraint

Lack of viable treatment options commercialized for the treatment of disease/disorder rather than the symptoms associated with the disease; this factor is expected to restrain the market growth
High cost of treatment for the disorder is expected to act as a restraint to the market growth

Get Full Table Of content @ https://www.databridgemarketresearch.com/toc/?dbmr=global-thalassemia-market

About Data Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact:
Data Bridge Market Research
Tel: +1-888-387-2818
Email: [email protected]

Close